All In Biotech

Drug Trial Radar · NCT04829318

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

183

Actual

Start

Apr 26, 2021

Primary completion

Jul 22, 2024

Study completion Jul 22, 2024

Sponsor

Lead sponsor
Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).

Conditions

  • Depressive Disorder, Major

Interventions

  • EsketamineDrug

    Esketamine will be self-administered as nasal spray.

  • SSRI/SNRIDrug

    Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  2. Incidence Rate of Treatment-emergent Adverse Events (TEAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  3. Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  4. Incidence Rate of Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  5. Percentage of of Participants With TEAEs Leading to DeathTime frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  6. Incidence Rate of TEAEs Leading to DeathTime frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  7. Percentage of Participants With Treatment-emergent AEs of Special Interest (AESIs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  8. Incidence Rate of Treatment-emergent AEs of Special Interest (AESIs)Time frame: From Day 1 of study 54135419TRD4010 up to 30 days after last dose of study drug at Week 104 (up to Week 108)
  9. Number of Participants With Suicidal Ideation and Behavior in Study 54135419TRD4010 as Assessed by Columbia-suicide Severity Rating Scale (C-SSRS) ScoreTime frame: Baseline (Day 1 of Study 54135419TRD3013) up to Week 104 of study 54135419TRD4010 (up to Week 136)

Locations

59 sites in 14 countries. Site status is shown where the registry gives one.

  • FunDaMos

    Buenos Aires, Argentina

  • CEN Consultorios Especializados en Neurociencias

    Córdoba, Argentina

  • Fundacion Lennox

    Córdoba, Argentina

  • Instituto Medico DAMIC

    Córdoba, Argentina

  • Sanatorio Prof Leon S Morra S A

    Córdoba, Argentina

  • Instituto de Neurociencias San Agustin

    La Plata, Argentina

  • C I A P Centro de investigacion y Asistencia en Psiquiatria

    Rosario, Argentina

  • Anima

    Alken, Belgium

  • Mental Health Center - Rousse

    Rousse, Bulgaria

  • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum

    Sofia, Bulgaria

  • Centre for Mental Health Prof.N.Shipkovenski EOOD

    Sofia, Bulgaria

  • Psychiatricka ambulance Saint Anne s.r.o.

    Brno, Czechia

  • Psychiatricka ambulance, MUDr. Marta Holanova

    Brno, Czechia

  • NeuropsychiatrieHK, s.r.o.

    Hradec Králové, Czechia

  • A Shine S R O

    Pilsen, Czechia

  • AD71 s.r.o.

    Prague, Czechia

  • Medical Services Prague S R O

    Prague, Czechia

  • Institut Neuropsychiatricke pece

    Prague, Czechia

  • Mederon LTD at ARTES

    Helsinki, Finland

  • Medizinisches Versorgungszentrum LiO GmbH

    Berlin, Germany

  • Praxis Dr. med. Kirsten Hahn

    Berlin, Germany

  • Klinikum Dortmund gGmbH

    Dortmund, Germany

  • Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik

    Freiburg im Breisgau, Germany

  • Klinische Forschung Hamburg

    Hamburg, Germany

  • Oberhavel Kliniken GmbH

    Hennigsdorf, Germany

  • Pharmakologisches Studienzentrum Chemnitz GmbH

    Mittweida, Germany

  • Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik

    Pfaffenhofen, Germany

  • Somni Bene GmbH

    Schwerin, Germany

  • Klinische Forschung Schwerin GmbH

    Schwerin, Germany

  • Psychiatric Clinic 'Agios Charalampos'

    Heraklion, Greece

  • University General Hospital of Rio Patras

    Pátrai, Greece

  • G Papanikolaou Hospital of Thessaloniki

    Thessaloniki, Greece

  • Processus Kft

    Budapest, Hungary

  • Bugat Pal Korhaz

    Gyöngyös, Hungary

  • Petz Aladar Megyei Oktato Korhaz

    Győr, Hungary

  • Hospital Raja Permaisuri Bainun

    Ipoh, Malaysia

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Hospital Pengajar Universiti Putra Malaysia

    Serdang, Malaysia

  • Hospital Tuanku Jaafar

    Seremban, Malaysia

  • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk

    Bialystok, Poland

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.